Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use.
CONCLUSIONS: The landscape of PARP inhibitor use for ovarian cancer is rapidly evolving and PARP inhibitors have become more available as a targeted therapy option for ovarian cancer treatment.
PMID: 28994564 [PubMed - as supplied by publisher]
Source: Minerva Ginecologica - Category: OBGYN Tags: Minerva Ginecol Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Clinical Trials | Conferences | Ovarian Cancer | Ovaries | Study | USA Health